Zimmer Biomet Holdings Inc

Zimmer Biomet Holdings Inc

ZBH

Get informed when a big investor buys or sells

+ Follow
Market Cap$17.02B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Zimmer Biomet Holdings IncZimmer Biomet Holdings Inc22.51.09%4%2.70.5

Earnings Call Q2 2025

August 7, 2025 - AI Summary

Q2 Performance & Growth Outlook: Zimmer Biomet reported a 2.8% organic constant currency revenue growth in Q2 2025, with positive contributions from the U.S. Hips (up 5.2%) and Knees (up 1.7%). For the full year, the company raised its organic revenue growth guidance to 3.5%-4.5%, previously 3%-5%, and expects Paragon 28 to contribute an additional 270 basis points.
Adjusted Earnings Guidance: The company increased its adjusted EPS forecast for 2025 to $8.10-$8.30, from $7.90-$8.10, reflecting strong operational efficiencies, reduced tariff impacts, and favorable foreign exchange conditions. This suggests a commitment to profitability in a challenging market environment.
Strategic Acquisitions: The acquisition of Monogram Technologies was highlighted as a pivotal event for the company, aimed at advancing Zimmer Biomet’s robotics capabilities. The deal is expected to be neutral to adjusted EPS between 2025 and 2027, with potential revenue contributions beginning in 2027.

Exclusive for Stockcircle Pro members

Sign upSign Up
$93.20

Target Price by Analysts

7% upsideZimmer Biomet Holdings Target Price DetailsTarget Price
$275.34

Current Fair Value

216.2% upside

Undervalued by 216.2% based on the discounted cash flow analysis.

Share Statistics

Market cap$17.02 Billion
Enterprise Value$24.07 Billion
Dividend Yield$0.96 (1.09%)
Earnings per Share$3.56
Beta0.47
Outstanding Shares195,000,000

Return

Return on Equity4.13%ROE
Return on Assets2.68%
Return on Invested Capital4.84%

Valuation & Multiples

P/E Ratio22.53P/E Ratio
PEG-PEG
Price to Sales2.72Price to Sales
Price to Book Ratio1.16Price to Book Ratio
Enterprise Value to Revenue3.8
Enterprise Value to EBIT23.63
Enterprise Value to Net Income39
Total Debt to Enterprise0.31
Debt to Equity0.51Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 4, 2026
EPS Estimate
$1.86
Average shareholder expectation
Revenue Estimate
$2.05 B
Average shareholder expectation

Next Earnings Call

Expected Date
August 6, 2026
EPS Estimate
$1.99
Average shareholder expectation
Revenue Estimate
$2.14 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio1.1402▼ 123.86%
Total Calls261,800▲ 2.03%
Total Puts298,500▼ 51.10%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %97.53%▼ 3.64%
Total Invested$17.37B▼ 12.54%
Investors Holding924▼ 41.00%

ESG Score

No data

About Zimmer Biomet Holdings Inc

CEO: Bryan Hanson

Relevant Senate Committees

Finance

Controls taxation, trade, and entitlement spending (Medicare/Medicaid), which directly impacts ZBH's profitability through tax policy and influences demand for its products via reimbursement rates.

Appropriations

Directly allocates federal funding for various agencies, including healthcare programs and research initiatives, which can significantly impact ZBH's market opportunities and sales to government entities.

Health, Education, Labor, and Pensions

Direct oversight of the FDA, which is critical for medical device approval and regulation. Also influences labor policies, which affect manufacturing costs.

Judiciary

Jurisdiction over intellectual property (patents) and antitrust laws is highly relevant. Patents are crucial for medical device companies, and antitrust enforcement could impact M&A activity.

Veterans' Affairs

Direct oversight of the Department of Veterans Affairs (VA), a significant purchaser of medical devices. Funding and policy decisions directly impact ZBH's sales to veterans' healthcare systems.